Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Endemic Poultry Viral Diseases Research » Research » Publications at this Location » Publication #339802

Research Project: Intervention Strategies to Prevent and Control Enteric Diseases of Poultry

Location: Endemic Poultry Viral Diseases Research

Title: Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy

Author
item Wu, Yunzhou - Northeast Agricultural University
item He, Jinjiao - Xianxiang University
item Geng, Jingshu - Harbin Medical University
item An, Ying - Northeast Agricultural University
item Ye, Xianlong - Henan Normal University
item Yan, Shijun - Northeast Agricultural University
item Yu, Qingzhong
item Yin, Jiechao - Northeast Agricultural University
item Zhang, Zhenyu - Harbin Veterinary Research Institute
item Li, Deshan - Northeast Agricultural University

Submitted to: European Journal of Pharmacology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 2/24/2017
Publication Date: 5/4/2017
Citation: Wu, Y., He, J., Geng, J., An, Y., Ye, X., Yan, S., Yu, Q., Yin, J., Zhang, Z., Li, D. 2017. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. European Journal of Pharmacology. 802:85–92. doi:org/10.1016/j.ejphar.2017.02.042.

Interpretive Summary: Newcastle disease virus (NDV) have shown anticancer therapeutic efficacy in preclinical studies and are currently proved for clinical trials. We have previously reported that NDV Anhinga strain has an efficient cancer therapeutic efficacy in liver tumor. A cytokine, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), can selectively kill various cancer cells without toxicity to most normal cells. In this study, we aimed to combine these two anticancer factors by engineering a NDV Anhinga strain-based recombinant virus expressing soluble TRAIL (NDV/Anh-TRAIL) as a cancer therapeutic agent. Administration of the NDV/Anh-TRAIL virus into liver tumor of an animal model results in an efficient suppression of hepatocellular carcinoma without significant toxicity. The results suggest that the recombinant NDV Anhinga strain expressing soluble TRAIL is a promising candidate for hepatoma therapy.

Technical Abstract: Newcastle disease virus (NDV) have shown oncolytic therapeutic efficacy in preclinical studies and are currently proved for clinical trials. We have previously reported, for the first time, NDV Anhinga strain has an efficient cancer therapeutic efficacy in hepatoma. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential use of recombinant soluble TRAIL as a cancer therapeutic agent. In this study, we have showed administration of a recombinant NDV Anhinga strain expressing soluble TRAIL (NDV/Anh-TRAIL) results in an efficient suppression of hepatocellular carcinoma without significant toxicity. The results show that recombinant NDV Anhinga strain expressing soluble TRAIL is a promising candidate for hepatoma therapy.